Literature DB >> 19491823

The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer.

J W Poley1, I Kluijt, D J Gouma, F Harinck, A Wagner, C Aalfs, C H J van Eijck, A Cats, E J Kuipers, Y Nio, P Fockens, M J Bruno.   

Abstract

OBJECTIVES: Approximately 10-15% of all pancreatic cancers (PCs) may be hereditary in origin. We investigated the use of endoscopic ultrasonography (EUS) for the screening of individuals at high risk for developing PC. In this paper the results of first-time screening with EUS are presented.
METHODS: Those eligible for screening in this study were first-degree family members of affected individuals from familial pancreatic cancer (FPC) families, mutation carriers of PC-prone hereditary syndromes, individuals with Peutz-Jeghers syndrome, and mutation carriers of other PC-prone hereditary syndromes with clustering (> or =2 cases per family) of PC. All individuals were asymptomatic and had not undergone EUS before.
RESULTS: Forty-four individuals (M/F 18/26), aged 32-75 years underwent screening with EUS. Thirteen were from families with familial atypical multiple-mole melanoma (FAMMM), 21 with FPC, 3 individuals were diagnosed with hereditary pancreatitis, 2 were Peutz-Jeghers patients, 3 were BRCA1 and 2 were BRCA2 mutation carriers with familial clustering of PC, and 1 individual had a p53 mutation. Three (6.8%) patients had an asymptomatic mass lesion (12, 27, and 50 mm) in the body (n=2) or tail of the pancreas. All lesions were completely resected. Pathology showed moderately differentiated adenocarcinomas with N1 disease in the two patients with the largest lesions. EUS showed branch-type intraductal papillary mucinous neoplasia (IPMN) in seven individuals.
CONCLUSIONS: Screening of individuals at a high risk for PC with EUS is feasible and safe. The incidence of clinically relevant findings at first screening is high with asymptomatic cancer in 7% and premalignant IPMN-like lesions in 16% in our series. Whether screening improves survival remains to be determined, as does the optimal screening interval with EUS.

Entities:  

Mesh:

Year:  2009        PMID: 19491823     DOI: 10.1038/ajg.2009.276

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  106 in total

Review 1.  Familial pancreatic cancer--current knowledge.

Authors:  Detlef K Bartsch; Thomas M Gress; Peter Langer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-06-05       Impact factor: 46.802

2.  [Chronic pancreatitis as a risk factor for the development of pancreatic cancer--diagnostic challenges].

Authors:  Tilman Pickartz; Julia Mayerle; Matthias Kraft; Matthias Evert; Katja Evert; Jens-Peter Kühn; Claus-Dieter Heidecke; Markus M Lerch
Journal:  Med Klin (Munich)       Date:  2010-04

3.  Targeted screening of individuals at high risk for pancreatic cancer: results of a simulation model.

Authors:  Pari V Pandharipande; Curtis Heberle; Emily C Dowling; Chung Yin Kong; Angela Tramontano; Katherine E Perzan; William Brugge; Chin Hur
Journal:  Radiology       Date:  2014-11-12       Impact factor: 11.105

Review 4.  Review of screening for pancreatic cancer in high risk individuals.

Authors:  Alina Stoita; Ian D Penman; David B Williams
Journal:  World J Gastroenterol       Date:  2011-05-21       Impact factor: 5.742

5.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

Review 6.  Familial pancreatic cancer--status quo.

Authors:  Volker Fendrich; Peter Langer; Detlef K Bartsch
Journal:  Int J Colorectal Dis       Date:  2013-08-16       Impact factor: 2.571

Review 7.  To cease or 'de-cyst'? The evaluation and management of pancreatic cystic lesions.

Authors:  Brintha K Enestvedt; Nuzhat Ahmad
Journal:  Curr Gastroenterol Rep       Date:  2013-10

8.  Linear-array EUS improves detection of pancreatic lesions in high-risk individuals: a randomized tandem study.

Authors:  Eun Ji Shin; Mark Topazian; Michael G Goggins; Sapna Syngal; John R Saltzman; Jeffrey H Lee; James J Farrell; Marcia I Canto
Journal:  Gastrointest Endosc       Date:  2015-04-27       Impact factor: 9.427

Review 9.  ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes.

Authors:  Sapna Syngal; Randall E Brand; James M Church; Francis M Giardiello; Heather L Hampel; Randall W Burt
Journal:  Am J Gastroenterol       Date:  2015-02-03       Impact factor: 10.864

10.  Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance.

Authors:  Masaya Suenaga; Jun Yu; Koji Shindo; Koji Tamura; Jose Alejandro Almario; Christopher Zaykoski; P Dane Witmer; Shahriar Fesharakizadeh; Michael Borges; Anne-Marie Lennon; Eun-Ji Shin; Marcia Irene Canto; Michael Goggins
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.